Introduction
Flunitrazepam (FZP) is commonly used clinically for the induction of anesthesia. 1 It has also been reported that intravenous injection of FZP relieves prolonged seizures. 2 Epilepsy with continuous spikes and waves during slow wave sleep (CSWS) is an unclassified condition 3 observed mainly in cases of refractory epilepsy. In this report, we describe our treatment of two boys with CSWS. Informed consent was obtained prior to treatment.
Case reports
Patient 1: N.K., 9-year-old male ( Fig. 1) The patient's developmental milestones were normal until he experienced non-convulsive status epilepticus at the age of 9 years and nine months. His speech deteriorated dramatically, and his IQ score of WISC-R declined to 54. Waking EEG records showed diffuse spike and wave complexes which were attenuated by eye opening (Fig. 1A) . Continuous bursts of slow spike and wave complexes occurred without any clinical symptoms during non-REM sleep (Fig. 1B) . He was diagnosed as having CSWS. An intravenous injection of FZP at a dose of 0.02 mg/kg brought his EEG readings back to normal (Fig. 1C ). Brain images (CT and MRI) were also normal. He was treated thereafter with oral FZP (0.002 mg/kg/day) for 2 weeks and a longer course of valpronic acid, and followed a satisfactory course including gradual recovery of his mental development. He finally graduated from elementary school and then junior high school.
Patient 2: C.K., 7-year-old male (Fig. 2) This patient had a history of simple febrile seizures (1 year). From the age of 7 years and nine months, he suffered lost consciousness with automatism for several minutes early each morning; he also had dysarthria, sometimes spoke meaninglessly, and suffered from decreased perception. However, he was able to go to school by himself and experienced no aphasia. Sleep EEG readings recorded at our clinic revealed diffuse spike and wave complexes which were considered to show electrical status ( Fig. 2A) . He was diagnosed as having CSWS. An intravenous injection of FZP at a dose of 0.02 mg/kg returned EEG readings to normal (Fig. 2B) , and they stayed in the normal range for more than 20 min (Fig. 2C) . The patient woke up 30 min after the injection, and his responses to subsequent questions were appropriate. His brain images (CT, MRI and SPECT) were normal. He was treated thereafter in the same way as Patient 1. He regained smooth speech patterns and completed elementary school satisfactorily.
Discussion
Epilepsy with CSWS is defined by Tassinari et al. 4 and epileptic seizures with CSWS are thought to be intractable even with polytherapy involving antieleptic drugs. 5 Several reports had documented the potent anticonvulsive effects of FZP in animals 6 and humans, 2,7 so we decided to try it on two patients with CSWS. We were able to demonstrate its efficacy in inhibiting electrical status on EEG. Long-term use of FZP is likely to result in side effects (intolerance, drowsiness, etc), but it seems to be a good reliever of ictal states with CSWS. It has been reported that some patients with CSWS can be regarded as Landau-Kleffner syndrome (LKS) sufferers. 8, 9 Indeed, it is suspected that CSWS syndrome and LKS may well be two sides of the same coin. 5 Because of their satisfactory long-term outcomes, we diagnosed the two present cases as having LKS. 5 Although no previous reports have indicated the use of FZP for CSWS, we suggest from our experience with the two cases described here that it may be a beneficial treatment. 
